The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.

Authors

Chee Lee

NHMRC Clinical Trials Centre, Sydney, Australia

Chee Lee , Lucy Claire Davies , Yi-Long Wu , Tetsuya Mitsudomi , Akira Inoue , Rafael Rosell , Caicun Zhou , Kazuhiko Nakagawa , Sumitra Throngprasert , Masahiro Fukuoka , Richard J. Gralla , Val Gebski , Tony Mok , James Chih-Hsin Yang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A meta-analysis of smoking status on clinical outcomes of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor.

First Author: Yoshikazu Hasegawa

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.

First Author: Christos Chouaid

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).

First Author: Bartomeu Massuti

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).

First Author: Rosario Garcia Campelo